Report Summary
Summary
Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by loss of interest and pleasure in enjoyable environment. People are affected in different ways by major depression. Some people have trouble sleeping, feel agitated and irritable, and have sudden weight loss. Moreover, they can have other mental and physical symptoms such as fatigue, memory loss, feeling of hopelessness, body aches, headaches, and thoughts of suicide.
In terms of geography, North America dominates the global major depressive disorder market due to increased awareness about various depression conditions in the region. The U.S. represents the largest market for major depressive disorder in North America, followed by Canada. In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the major depressive disorder market. This market in Asia is expected to expand at a significant rate over the next five years. This is due to various companies setting up manufacturing facilities in the region. Moreover, increasing awareness about various depression episodes and rise in geriatric population are also driving the growth of the market in the region. India, China, and Japan are expected to be the fastest growing major depressive disorder markets in Asia.
In 2020, the global Major Depressive Disorder Therapeutic market size was xx million US$ and it is expected to reach xx million US$ by the end of 2027, with a CAGR of xx% between 2021 and 2027.
This report studies the Major Depressive Disorder Therapeutic market size by players, regions, product types and end industries, history data 2017-2020 and forecast data 2021-2027; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
This report focuses on the global top players, covered
Pfizer
Eli Lilly
H. Lundbeck
Otsuka Pharmaceutical
AstraZeneca
Alkermes
Takeda Pharmaceutical
Naurex
Euthymics Bioscience
E-therapeutics
Market segment by Regions/Countries, this report covers
North America
Europe
China
Rest of Asia Pacific
Central & South America
Middle East & Africa
Market segment by Type, the product can be split into
Drugs Therapy
Biological Therapy
Meditation
Physiotherapy
Other
Market segment by Application, the market can be split into
Under 25 Years Old
25-45 Years Old
Above 45 Years Old
The study objectives of this report are:
To study and forecast the market size of Major Depressive Disorder Therapeutic in global market.
To analyze the global key players, SWOT analysis, value and global market share for top players.
To define, describe and forecast the market by type, end use and region.
To analyze and compare the market status and forecast among global major regions.
To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Major Depressive Disorder Therapeutic are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2020
Forecast Year 2021 to 2027
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders
Raw material suppliers
Distributors/traders/wholesalers/suppliers
Regulatory bodies, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade associations and industry bodies
End-use industries
Available Customizations
With the given market data, EternityInsights offers customizations according to the company's specific needs. The following customization options are available for the report:
Further breakdown of Major Depressive Disorder Therapeutic market on basis of the key contributing countries.
Detailed analysis and profiling of additional market players.
Table Of Contents
Table of Contents
Major Depressive Disorder Therapeutic Market Report by Company, Regions, Types and Applications, Global Status and Forecast to 2025
1 Industry Overview of Major Depressive Disorder Therapeutic
1.1 Major Depressive Disorder Therapeutic Market Overview
1.1.1 Major Depressive Disorder Therapeutic Product Scope
1.1.2 Market Status and Outlook
1.2 Global Major Depressive Disorder Therapeutic Market Size and Analysis by Regions
1.2.1 North America
1.2.2 Europe
1.2.3 China
1.2.4 Rest of Asia Pacific
1.2.5 Central & South America
1.2.6 Middle East & Africa
1.3 Major Depressive Disorder Therapeutic Market by Type
1.3.1 Drugs Therapy
1.3.2 Biological Therapy
1.3.3 Meditation
1.3.4 Physiotherapy
1.3.5 Other
1.4 Major Depressive Disorder Therapeutic Market by End Users/Application
1.4.1 Under 25 Years Old
1.4.2 25-45 Years Old
1.4.3 Above 45 Years Old
2 Global Major Depressive Disorder Therapeutic Competition Analysis by Players
2.1 Major Depressive Disorder Therapeutic Market Size (Value) by Players (2019 and 2020)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future
3 Company (Top Players) Profiles
3.1 Pfizer
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Major Depressive Disorder Therapeutic Revenue (Value) (2017-2020)
3.1.5 Recent Developments
3.2 Eli Lilly
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Major Depressive Disorder Therapeutic Revenue (Value) (2017-2020)
3.2.5 Recent Developments
3.3 H. Lundbeck
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Major Depressive Disorder Therapeutic Revenue (Value) (2017-2020)
3.3.5 Recent Developments
3.4 Otsuka Pharmaceutical
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Major Depressive Disorder Therapeutic Revenue (Value) (2017-2020)
3.4.5 Recent Developments
3.5 AstraZeneca
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Major Depressive Disorder Therapeutic Revenue (Value) (2017-2020)
3.5.5 Recent Developments
3.6 Alkermes
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Major Depressive Disorder Therapeutic Revenue (Value) (2017-2020)
3.6.5 Recent Developments
3.7 Takeda Pharmaceutical
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Major Depressive Disorder Therapeutic Revenue (Value) (2017-2020)
3.7.5 Recent Developments
3.8 Naurex
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Major Depressive Disorder Therapeutic Revenue (Value) (2017-2020)
3.8.5 Recent Developments
3.9 Euthymics Bioscience
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Major Depressive Disorder Therapeutic Revenue (Value) (2017-2020)
3.9.5 Recent Developments
3.10 E-therapeutics
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Major Depressive Disorder Therapeutic Revenue (Value) (2017-2020)
3.10.5 Recent Developments
4 Global Major Depressive Disorder Therapeutic Market Size by Type and Application (2017-2020)
4.1 Global Major Depressive Disorder Therapeutic Market Size by Type (2017-2020)
4.2 Global Major Depressive Disorder Therapeutic Market Size by Application (2017-2020)
4.3 Potential Application of Major Depressive Disorder Therapeutic in Future
4.4 Top Consumer/End Users of Major Depressive Disorder Therapeutic
5 North America Major Depressive Disorder Therapeutic Development Status and Outlook
5.1 North America Major Depressive Disorder Therapeutic Market Size (2017-2020)
5.2 North America Major Depressive Disorder Therapeutic Market Size and Market Share by Players (2019 and 2020)
6 Europe Major Depressive Disorder Therapeutic Development Status and Outlook
6.1 Europe Major Depressive Disorder Therapeutic Market Size (2017-2020)
6.2 Europe Major Depressive Disorder Therapeutic Market Size and Market Share by Players (2019 and 2020)
7 China Major Depressive Disorder Therapeutic Development Status and Outlook
7.1 China Major Depressive Disorder Therapeutic Market Size (2017-2020)
7.2 China Major Depressive Disorder Therapeutic Market Size and Market Share by Players (2019 and 2020)
8 Rest of Asia Pacific Major Depressive Disorder Therapeutic Development Status and Outlook
8.1 Rest of Asia Pacific Major Depressive Disorder Therapeutic Market Size (2017-2020)
8.2 Rest of Asia Pacific Major Depressive Disorder Therapeutic Market Size and Market Share by Players (2019 and 2020)
9 Central & South America Major Depressive Disorder Therapeutic Development Status and Outlook
9.1 Central & South America Major Depressive Disorder Therapeutic Market Size (2017-2020)
9.2 Central & South America Major Depressive Disorder Therapeutic Market Size and Market Share by Players (2019 and 2020)
10 Middle East & Africa Major Depressive Disorder Therapeutic Development Status and Outlook
10.1 Middle East & Africa Major Depressive Disorder Therapeutic Market Size (2017-2020)
10.2 Middle East & Africa Major Depressive Disorder Therapeutic Market Size and Market Share by Players (2019 and 2020)
11 Market Forecast by Regions, Type and Application (2021-2027)
11.1 Global Major Depressive Disorder Therapeutic Market Size (Value) by Regions (2021-2027)
11.1.1 North America Major Depressive Disorder Therapeutic Revenue and Growth Rate (2021-2027)
11.1.2 Europe Major Depressive Disorder Therapeutic Revenue and Growth Rate (2021-2027)
11.1.3 China Major Depressive Disorder Therapeutic Revenue and Growth Rate (2021-2027)
11.1.4 Rest of Asia Pacific Major Depressive Disorder Therapeutic Revenue and Growth Rate (2021-2027)
11.1.5 Central & South America Major Depressive Disorder Therapeutic Revenue and Growth Rate (2021-2027)
11.1.6 Middle East & Africa Major Depressive Disorder Therapeutic Revenue and Growth Rate (2021-2027)
11.2 Global Major Depressive Disorder Therapeutic Market Size (Value) by Type (2021-2027)
11.3 Global Major Depressive Disorder Therapeutic Market Size by Application (2021-2027)
12 Major Depressive Disorder Therapeutic Market Dynamics
12.1 Major Depressive Disorder Therapeutic Market Opportunities
12.2 Major Depressive Disorder Therapeutic Challenge and Risk
12.2.1 Competition from Opponents
12.2.2 Downside Risks of Economy
12.3 Major Depressive Disorder Therapeutic Market Constraints and Threat
12.3.1 Threat from Substitute
12.3.2 Government Policy
12.3.3 Technology Risks
12.4 Major Depressive Disorder Therapeutic Market Driving Force
12.4.1 Growing Demand from Emerging Markets
12.4.2 Potential Application
13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
13.3.1 Economic Fluctuations
13.3.2 Other Risk Factors
14 Research Finding/Conclusion
15 Appendix
Methodology
Analyst Introduction
Data Source
